EUVIMEDEUVIMED entdecken
Open Access

Heterozygous and generalist MxA super-restrictors overcome breadth-specificity trade-offs in antiviral restriction

Rechel A Geiger iD, Damini Khera, Jeannette L Tenthorey iD, Georg Kochs iD, Laura Graf iD, Michael Emerman iD, Harmit S Malik iD

Science Advances · 2025

DOI: 10.1126/sciadv.adu0062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Rechel A Geiger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Scientist Training Program, University of Washington School of Medicine, Seattle, WA 98195, USA. Hauptthemen laut MEDLINE: Myxovirus Resistance Proteins, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NHGRI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiviral restriction factors such as MxA (myxovirus resistance protein A) inhibit many viruses. Viral escape drives restriction factors to evolve rapidly at virus-binding interfaces to regain defense. Here, we explore how antiviral proteins balance restricting many viruses with evolving specificity against individual viruses. Human MxA uses its rapidly evolving loop L4 as the specificity determinant for orthomyxoviruses such as thogotovirus (THOV) and influenza (IAV). Previous combinatorial mutagenesis of rapidly evolving residues in human MxA loop L4 identified THOV “super-restrictors” and suggested an antiviral breadth-specificity trade-off. Using a modified combinatorial mutagenesis strategy, we find super-restrictor MxA variants specific to H5N1 IAV. A single L4 residue underlies the MxA breadth-specificity trade-off. However, rare “generalist” super-restrictors or a heterozygous combination of more common “specialist” super-restrictors can overcome the breadth-specificity trade-off. Our findings suggest that at least two strategies enable restriction factors such as MxA to increase their restriction of diverse viruses to overcome breadth-specificity trade-offs, which might be pervasive in host-virus conflicts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myxovirus Resistance ProteinsAntiviral AgentsHumansInfluenza A Virus, H5N1 SubtypeThogotovirus

Substanzen

Myxovirus Resistance ProteinsMX1 protein, humanAntiviral Agents

Autor:innen und Institutionen

  • Medical Scientist Training Program, University of Washington School of Medicine, Seattle, WA 98195, USA.
  • Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA.
  • Division of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Department of Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158, USA.
  • Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.
  • Institute of Virology, Medical Center, University of Freiburg, 79104 Freiburg, Germany.

ORCID-Profile: Rechel A Geiger, Jeannette L Tenthorey, Georg Kochs, Laura Graf, Michael Emerman, Harmit S Malik

Förderung

  • NIGMS NIH HHS
  • NHGRI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Geiger, R. A., Khera, D., Tenthorey, J. L., Kochs, G., Graf, L., Emerman, M., & Malik, H. S. (2025). Heterozygous and generalist MxA super-restrictors overcome breadth-specificity trade-offs in antiviral restriction. Science Advances. https://doi.org/10.1126/sciadv.adu0062

Vancouver

Geiger RA, Khera D, Tenthorey JL, Kochs G, Graf L, Emerman M, et al. Heterozygous and generalist MxA super-restrictors overcome breadth-specificity trade-offs in antiviral restriction. Science Advances. 2025. doi:10.1126/sciadv.adu0062

BibTeX
@article{Geiger2025,
  author = {Geiger, Rechel A and Khera, Damini and Tenthorey, Jeannette L and Kochs, Georg and Graf, Laura and Emerman, Michael and Malik, Harmit S},
  title = {Heterozygous and generalist MxA super-restrictors overcome breadth-specificity trade-offs in antiviral restriction},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adu0062}
}
Kostenlos starten →